AI-generated summary
The authors reviewed seven published studies of low-level laser therapy used alongside standard care for bisphosphonate-related osteonecrosis of the jaw. They report an overall response rate of 55 percent with laser therapy, compared with 30 percent in controls, and suggest it may be worth adding. The authors also state that prospective, well-controlled studies are needed to confirm these results.
- Studies included
- 7
- Who or what was studied
- Cancer patients with bisphosphonate- or denosumab-associated osteonecrosis of the jaw
- Limits stated in the abstract
- The abstract states that further research is needed and that prospective well-controlled studies are warranted, implying the existing evidence is not yet conclusive.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Wound healing. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.